Since IDO1 inhibitors are now being developed clinically for the treatment of several cancers with the aim of reversing cancer-associated immune suppression [30], we speculate that a possible targeting of IDO1 in MB could improve tumor eradication by acting at different levels. The gene discussed is IDO1; the disease is cancer.